Key Highlights

  • Artrya signed a five-year commercial agreement with Huntsville Hospital Health System (HH Health), its first conversion of a SAPPHIRE Study participant into a commercial customer.
  • HH Health becomes Artrya's fourth U.S. commercial customer, joining Tanner Health, Northeast Georgia Health System and Cone Health, lifting the count from three to four.
  • The minimum contracted value is US$0.5M and relates to Salix Coronary Anatomy only, with additional fee-per-scan Revenue possible from Salix Coronary Plaque and, after FDA clearance, Salix Coronary Flow.
  • Salix is to be integrated into applicable clinical workflows across HH Health's 15-hospital network, Artrya's largest U.S. customer deployment to date.

Introduction: An AI Platform for Coronary Artery Disease

Artrya Limited (ASX:AYA) is an Australian medical technology company developing AI-powered solutions for the detection and management of coronary artery disease. Its Salix cloud platform supports real-time, point-of-care assessment, and its proprietary software analyses coronary CT scans to identify key biomarkers of heart disease.

The company states that regulatory and commercial activities are underway across key international markets, including the United States.

Latest Development: The Huntsville Hospital Health System Agreement

On 2 October 2026, Artrya announced a five-year commercial agreement with Huntsville Hospital Health System. The company described it as the first conversion of a SAPPHIRE Study participant into a commercial customer, expanding its U.S. commercial customer base from three to four.

On value, the agreement carries a minimum contracted value of US$0.5M. Artrya clarified that this figure relates to Salix Coronary Anatomy and does not include potential usage-based revenue from the Plaque and Flow modules. Revenue under the agreement is structured as recurring software-as-a-service subscription revenue for Coronary Anatomy, with fee-per-scan revenue from CCTA assessments performed with Salix Coronary Plaque and, following FDA clearance, Salix Coronary Flow.

The agreement extends the relationship with HH Health beyond the SAPPHIRE research collaboration into routine clinical use across applicable workflows within the broader health system. Artrya described HH Health as its largest customer to date, with the 15-hospital network representing its largest U.S. customer deployment.

Material terms disclosed include a non-exclusive SaaS licence for clinical use of Salix Coronary Anatomy, a monthly subscription fee, and fee-per-scan revenue for Coronary Plaque that is eligible for U.S. reimbursement under a Category I CPT code. Coronary Flow fee-per-scan revenue is eligible for reimbursement under a Category I CPT code once FDA cleared. The five-year term includes standard default provisions and customary termination provisions, along with security and privacy protocols, support levels and software upgrades. Artrya noted that the full details remain commercial in confidence.

Sector Context: SAPPHIRE and the U.S. Commercial Strategy

Artrya explained that SAPPHIRE forms part of its broader U.S. clinical and commercial strategy, establishing collaborations with leading, high-volume cardiovascular centres while giving participating organisations direct exposure to the Salix platform. The HH Health agreement is presented as the first example of a participant progressing from clinical research engagement to commercial adoption.

Chief Executive John Konstantopoulos said the company's focus is on deploying Salix across its four U.S. customers while continuing to progress its SAPPHIRE relationships and broader U.S. commercial activities.

What to Watch Ahead

Artrya will host an investor webinar at 12.00pm AEDT (9.00am AWST) on Wednesday, 7 October 2026 to discuss the HH Health announcement, including a Q&A session. A recording will be available on the Investor Centre section of the company's website for 60 days.

Other items referenced in the announcement include the FDA clearance still required for Salix Coronary Flow, the deployment of Salix across the four U.S. customers, and progress with the remaining SAPPHIRE participants.

The Bottom Line

Artrya (ASX:AYA) has added its fourth U.S. commercial customer through a five-year agreement that carries a US$0.5M minimum contracted value for Coronary Anatomy. Revenue from the Plaque and Flow modules is usage-based and not included in that figure, and the Flow module still requires FDA clearance. The investor webinar on 7 October 2026 provides the next scheduled update from management.